FLT3 and leukemia: A recent clinical trial with the FLT3 inhibitor lestaurtinib revealed that patients whose leukemia blasts exhibited sensitivity to FLT3 inhibition ex vivo experienced benefits from the addition of the FLT3 inhibitor to chemotherapy [18].